Alcami is engaged in providing customisable and latest solutions for analytical development, clinical to commercial sterile and oral solid manufacturing, packaging, microbiology, cGMP biostorage, pharmaceutical support services and environmental monitoring

national-cancer-institute-KMvoHcB-w5g-unsplash

GHO and The Vistria Group have acquired the CDMO Alcami. (Credit: Photo by National Cancer Institute on Unsplash)

UK-based Global Healthcare Opportunities (GHO Capital Partners) and The Vistria Group have acquired the pharmaceutical contract development and manufacturing organisation (CDMO), Alcami, for an undisclosed sum.

Alcami was acquired from funds affiliated with Madison Dearborn Partners (MDP) and Ampersand Capital Partners.

Based in North Carolina, Alcami has five campuses in the US. The locations support fill-finish and oral solid-dose drug product manufacturing; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals, and materials.

With a total plant area of 738,000ft², the firm serves pharmaceutical and biotech companies of all sizes providing customisable solutions for analytical development.

GHO Capital and The Vistria Group have purchased a 50/50 controlling interest in Alcami from funds affiliated with MDP and Ampersand.

As part of the deal, Ampersand and Alcami Management committed a sizeable amount of equity.

GHO is a specialist healthcare investment advisor which creates high-growth healthcare opportunities and targets Pan-European and transatlantic internationalisation to set up companies of strategic global value.

It collaborates with management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery for faster and more accessible healthcare.

The Vistria Group is said to be a private investment firm that invests in essential industries like healthcare, knowledge and learning, and financial services.

In January 2020, Alcami expanded its sterile fill-finish capacity with the acquisition of TriPharm Services. Located near Research Triangle Park, North Carolina, TriPharm Services is a new and advanced sterile fill-finish manufacturing centre.